| Literature DB >> 36230628 |
Virginia Lope1,2,3, Angel Guerrero-Zotano3,4, Emma Ruiz-Moreno1,2, Begoña Bermejo3,5,6,7, Silvia Antolín3,8, Álvaro Montaño3,9, José Manuel Baena-Cañada3,10, Manuel Ramos Vázquez3,11, Nerea Fernández de Larrea-Baz1,2,3, José Ignacio Chacón3,12, José Angel García-Sáenz3,6,13, Clara Olier3,14, Montserrat Muñoz3,15, Antonio Antón3,16, Pedro Sánchez Rovira3,17, Angels Arcusa Lanza3,18, Sonia González3,19, Amparo Oltra3,20, Joan Brunet3,21, Joaquín Gavilá Gregori3,4, María Teresa Martínez3,5, Lourdes Calvo3,8, Libertad Rosell3, Susana Bezares3, Roberto Pastor-Barriuso1,2, Beatriz Pérez-Gómez1,2,3, Miguel Martín3,6,22, Marina Pollán1,2,3.
Abstract
Breast cancer (BC) survivors are advised to follow the WCRF/AICR cancer prevention recommendations, given their high risk of developing a second tumour. We aimed to explore compliance with these recommendations in BC survivors and to identify potentially associated clinical and sociodemographic factors. A total of 420 BC survivors, aged 31-80, was recruited from 16 Spanish hospitals. Epidemiological, dietary and physical activity information was collected through questionnaires. A 7-item score to measure compliance with the recommendations was built according to the 2018 WCRF/AICR scoring criteria. Standardized prevalences and standardized prevalence ratios of moderate and high compliance across participant characteristics were estimated using multinomial and binary logistic regression models. The mean score was 3.9 (SD: 1.0) out of 7 points. Recommendations with the worst adherence were those of limiting consumption of red/processed meats (12% of compliance, 95% CI: 8.2-15.0) and high fibre intake (22% of compliance, 95% CI: 17.6-27.0), while the best compliance was observed for the consumption of fruits and vegetables (73% of compliance, 95% CI: 69.2-77.7). Overall, adherence was worse in women with university education and in those with first-degree relatives with BC. This information may be of interest to design and implement personalized preventive measures adapted to the characteristics of these patients.Entities:
Keywords: Health-EpiGEICAM; WCRF/AICR guidelines; breast cancer; cancer prevention recommendations; compliance; health behaviours; healthy lifestyle; lifestyle recommendations; survival
Year: 2022 PMID: 36230628 PMCID: PMC9561971 DOI: 10.3390/cancers14194705
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Operationalizing, scoring and adherence to 2018 WCRF/AICR recommendations in breast cancer survivors.
| 2018 WCRF/AICR Recommendations | Operationalization | Adherence | |
|---|---|---|---|
| (N = 420) | |||
| Points | n (%) | ||
| 1. Be a healthy weight | BMI (kg/m2): | ||
| 18.5–24.9 | 1 | 192 (45.7) | |
| 25–29.9 | 0.5 | 155 (36.9) | |
| <18.5 or | 0 | 73 (17.4) | |
| 2. Be physically active | Total moderate-vigorous physical activity (min/wk): | ||
| 1 | 145 (34.5) | ||
| 150-<300 | 0.5 | 121 (28.8) | |
| <150 | 0 | 154 (36.7) | |
| 3. Eat a diet rich in wholegrains, vegetables, fruit and beans | Fruits and vegetables (g/day): | ||
| 0.5 | 309 (73.6) | ||
| 200-<400 | 0.25 | 85 (20.2) | |
| <200 | 0 | 26 (6.2) | |
| Total fibre (g/day): | |||
| 0.5 | 57 (13.6) | ||
| 15-<30 | 0.25 | 247 (58.8) | |
| <15 | 0 | 116 (27.6) | |
| 4. Limit consumption of “fast foods” and other processed foods high in fat, starches or sugars | Percent of total kcal from ultra-processed foods (aUPFs): | ||
| Tertile 1 (<14.0) | 1 | 140 (33.3) | |
| Tertile 2 (14.0–20.9) | 0.5 | 140 (33.3) | |
| Tertile 3 (>20.9) | 0 | 140 (33.3) | |
| 5. Limit consumption of red and processed meat | Total red meat (g/wk) and processed meat (g/wk): | ||
| Red meat <500 and processed meat <21 | 1 | 45 (10.7) | |
| Red meat <500 and processed meat 21-<100 | 0.5 | 134 (31.9) | |
| Red meat | 0 | 241 (57.4) | |
| 6. Limit consumption of sugar-sweetened drinks | Total sugar-sweetened drinks (g/day): | ||
| 0 | 1 | 229 (54.5) | |
| >0- | 0.5 | 176 (41.9) | |
| >250 | 0 | 15 (3.6) | |
| 7. Limit alcohol consumption | Total ethanol (g/day): | ||
| 0 | 1 | 121 (28.8) | |
| 0.5 | 260 (61.9) | ||
| >14 (1 drink) | 0 | 39 (9.3) | |
Sociodemographic and clinical characteristics of breast cancer survivors, overall and by tertiles of the 2018 WCRF/AICR score.
| Adherence to WCRF/AICR Recommendations | ||||||
| Total | Low | Moderate | High | |||
| (1.25–3.25) | (3.50–4.25) | (4.50–7) | ||||
| n (%) | n (%) | n (%) | n (%) | |||
| Total | 420 (100.0) | 139 (33.1) | 151 (36.0) | 130 (31.0) | ||
| Adherence score, mean (SD) | 3.9 (1.0) | |||||
| Age, mean (SD) | 59.1 (9.0) | 57.6 (8.9) | 59.5 (9.2) | 60.2 (8.8) | 0.014 | |
| Educational level | ||||||
| Primary education or less | 156 (37.7) | 46 (33.6) | 56 (37.8) | 54 (41.9) | 0.016 | |
| High school/vocational training | 133 (32.1) | 49 (35.8) | 36 (24.3) | 48 (37.2) | ||
| University graduate | 125 (30.2) | 42 (30.7) | 56 (37.8) | 27 (20.9) | ||
| Marital status | ||||||
| With partner | 308 (73.5) | 99 (71.2) | 113 (75.3) | 96 (73.8) | 0.727 | |
| Without partner | 111 (26.5) | 40 (28.8) | 37 (24.7) | 34 (26.2) | ||
| Currently working | ||||||
| No | 250 (60.7) | 70 (51.5) | 92 (61.7) | 88 (69.3) | 0.012 | |
| Yes | 162 (39.3) | 66 (48.5) | 57 (38.3) | 39 (30.7) | ||
| Currently smoking | ||||||
| No | 340 (81.3) | 101 (73.2) | 125 (82.8) | 114 (88.4) | 0.005 | |
| Yes | 78 (18.7) | 37 (26.8) | 26 (17.2) | 15 (11.6) | ||
| Energy intake kcal/d, mean (SD) | 1775.0 (571.2) | 1865.5 (628.8) | 1746.0 (520.0) | 1711.9 (555.4) | 0.026 | |
| Parity | ||||||
| Parous | 346 (82.8) | 120 (86.3) | 119 (79.3) | 107 (82.9) | 0.289 | |
| Nulliparous | 72 (17.2) | 19 (13.7) | 31 (20.7) | 22 (17.1) | ||
| Family history of breast cancer | ||||||
| None | 227 (54.0) | 73 (52.5) | 71 (47.0) | 83 (63.8) | 0.062 | |
| Second degree only | 67 (16.0) | 22 (15.8) | 26 (17.2) | 19 (14.6) | ||
| First degree | 126 (30.0) | 44 (31.7) | 54 (35.8) | 28 (21.5) | ||
| Number of comorbidities | ||||||
| ≤1 | 134 (35.4) | 53 (41.7) | 42 (30.9) | 39 (33.6) | 0.396 | |
| 2–3 | 152 (40.1) | 44 (34.6) | 58 (42.6) | 50 (43.1) | ||
| >3 | 93 (24.5) | 30 (23.6) | 36 (26.5) | 27 (23.3) | ||
| Menopausal status at diagnosis | ||||||
| Pre/perimenopausal | 240 (61.9) | 85 (67.5) | 84 (60.0) | 71 (58.2) | 0.276 | |
| Postmenopausal | 148 (38.1) | 41 (32.5) | 56 (40.0) | 51 (41.8) | ||
| Years since diagnosis | 10.0 (1.0) | 9.9 (0.9) | 10.0 (1.0) | 10.0 (1.0) | 0.792 | |
| Tumour subtype a | ||||||
| HR+ | 301 (71.7) | 97 (69.8) | 108 (71.5) | 96 (73.8) | 0.704 | |
| HER2+ | 72 (17.1) | 28 (20.1) | 23 (15.2) | 21 (16.2) | ||
| TN | 47 (11.2) | 14 (10.1) | 20 (13.2) | 13 (10.0) | ||
| AJCC stage at diagnosis b | ||||||
| 0–I | 189 (45.4) | 57 (42.2) | 74 (49.0) | 58 (44.6) | 0.290 | |
| II | 176 (42.3) | 66 (48.9) | 56 (37.1) | 54 (41.5) | ||
| III–IV | 51 (12.3) | 12 (8.9) | 21 (13.9) | 18 (13.0) | ||
| Cancer treatment | ||||||
| Chemotherapy | 311 (74.4) | 106 (76.8) | 110 (72.8) | 95 (73.6) | 0.722 | |
| Radiotherapy | 326 (78.0) | 106 (76.3) | 114 (75.5) | 106 (82.8) | 0.283 | |
| Hormonetherapy | 340 (81.0) | 111 (79.9) | 121 (80.1) | 108 (83.1) | 0.758 | |
| Targeted therapy | 63 (15.0) | 23 (16.5) | 21 (13.9) | 19 (14.6) | 0.812 | |
| Current cancer treatment | 57 (13.7) | 24 (17.5) | 17 (11.3) | 16 (12.4) | 0.267 | |
| Subsequent cancer c | 50 (11.9) | 18 (13.0) | 15 (9.9) | 17 (13.1) | 0.638 | |
a Tumour subtypes: HR+ = hormone receptor positive tumours (ooestrogen receptor, ER+ and/or progesterone receptor PR +, with HER2−); HER2+ = human epidermal growth factor receptor 2 positive tumours; TN = triple negative tumours (ER-, PR- and HER2-). b According to the 7th edition of the American Joint Committee on Cancer (AJCC) cancer staging manual [24]. c Recurrence or second primary invasive breast cancer.
Standardized prevalence ratios of moderate and high compliance with 2018 WCRF/AICR recommendations by sociodemographic and clinical characteristics of breast cancer survivors.
| Standardized Prevalence Ratio (95% CI) a | |||
| Moderate Compliance | High Compliance | ||
| Age, y b | |||
| <55 | 1.00 | 1.00 | |
| 55–61 | 1.01 (0.67–1.53) | 1.17 (0.79–1.74) | |
| >61 | 1.30 (0.74–2.28) | 0.74 (0.39–1.41) | |
| Educational level | |||
| Primary education or less | 1.00 | 1.00 | |
| High school/vocational training | 0.89 (0.61–1.30) | 0.97 (0.68–1.38) | |
| University graduate | 1.39 (0.98–1.98) | 0.59 (0.36–0.96) | |
| Marital status | |||
| With partner | 1.00 | 1.00 | |
| Without partner | 0.94 (0.67–1.34) | 0.83 (0.55–1.26) | |
| Currently working | |||
| No | 1.00 | 1.00 | |
| Yes | 0.86 (0.60–1.24) | 0.96 (0.65–1.41) | |
| Currently smoking | |||
| No | 1.00 | 1.00 | |
| Yes | 1.12 (0.78–1.61) | 0.69 (0.42–1.16) | |
| Energy intake, kcal/d b | |||
| <1486 | 1.00 | 1.00 | |
| 1486–1943 | 1.22 (0.87–1.71) | 0.81 (0.55–1.19) | |
| >1943 | 1.00 (0.68–1.46) | 0.91 (0.62–1.33) | |
| Parity | |||
| Parous | 1.00 | 1.00 | |
| Nulliparous | 1.27 (0.90–1.80) | 1.03 (0.67–1.59) | |
| Family history of breast cancer | |||
| None | 1.00 | 1.00 | |
| Second degree only | 1.12 (0.72–1.72) | 0.79 (0.50–1.24) | |
| First degree | 1.61 (1.19–2.19) | 0.60 (0.39–0.92) | |
| Number of comorbidities | |||
| ≤1 | 1.00 | 1.00 | |
| 2–3 | 1.25 (0.89–1.77) | 1.16 (0.81–1.68) | |
| >3 | 1.35 (0.92–1.99) | 0.98 (0.63–1.53) | |
| Menopausal status at diagnosis | |||
| Pre/perimenopausal | 1.00 | 1.00 | |
| Postmenopausal | 0.90 (0.55–1.45) | 1.38 (0.83–2.30) | |
| Years since diagnosis b | |||
| <9.53 | 1.00 | 1.00 | |
| 9.54–10.28 | 1.13 (0.79–1.60) | 0.75 (0.50–1.14) | |
| >10.28 | 1.00 (0.68–1.48) | 1.03 (0.70–1.53) | |
| Tumour subtype c | |||
| HR+ | 1.00 | 1.00 | |
| HER2+ | 0.84 (0.54–1.30) | 0.75 (0.47–1.22) | |
| TN | 1.10 (0.71–1.71) | 0.78 (0.44–1.39) | |
| AJCC stage at diagnosis d | |||
| 0–I | 1.00 | 1.00 | |
| II | 0.83 (0.60–1.15) | 0.97 (0.68–1.40) | |
| III–IV | 0.91 (0.57–1.44) | 1.33 (0.85–2.09) | |
| Cancer treatment | |||
| Chemotherapy | 0.91 (0.63–1.31 ) | 1.14 (0.74–1.76) | |
| Radiotherapy | 0.78 (0.57–1.07) | 1.39 (0.89–2.20) | |
| Hormonetherapy | 0.99 (0.63–1.57) | 1.20 (0.69–2.08) | |
| Targeted therapy | 1.29 (0.72–2.32) | 1.12 (0.54–2.30) | |
| Current cancer treatment | 0.89 (0.56–1.41) | 0.85 (0.50–1.44) | |
| Subsequent cancer e | 1.01 (0.58–1.76) | 1.06 (0.58–1.97) | |
a Standardized to the overall distribution of age, recruiting region, educational level, marital status, currently working, currently smoking, caloric intake, parity, family history of breast cancer, number of comorbidities, menopausal status at diagnosis, years since diagnosis, tumour subtype, AJCC stage at diagnosis and current cancer treatment in the entire sample of breast cancer survivors. b In tertiles. c Tumour subtypes: HR+ = hormone receptor positive tumours (oestrogen receptor, ER+ and/or progesterone receptor PR +, with HER2−); HER2+ = human epidermal growth factor receptor 2 positive tumours; TN = triple negative tumours (ER-, PR- and HER2-). d According to the 7th edition of the American Joint Committee on Cancer (AJCC) cancer staging manual [24]. e Recurrence or second primary invasive breast cancer.
Figure 1Standardised prevalence of high compliance with specific lifestyle recommendations by sociodemographic and clinical characteristics of breast cancer survivors (%). Standardised prevalence (95% CI) to the overall distribution of age, recruiting region, educational level, marital status, currently working, currently smoking, caloric intake, parity, family history of breast cancer, number of comorbidities, menopausal status at diagnosis, years since diagnosis, tumour subtype, AJCC stage at diagnosis, current cancer treatment and the overall adherence to the other recommendations in the entire sample of breast cancer survivors.
Figure 2Standardised prevalence of high compliance with specific dietary recommendations by sociodemographic and clinical characteristics of breast cancer survivors (%). Standardised prevalence (95% CI) to the overall distribution of age, recruiting region, educational level, marital status, currently working, currently smoking, caloric intake, parity, family history of breast cancer, number of comorbidities, menopausal status at diagnosis, years since diagnosis, tumour subtype, AJCC stage at diagnosis, current cancer treatment and the overall adherence to the other recommendations in the entire sample of breast cancer survivors.